W1. Research Committee to the Medical Research Council. Controlled trial of soya-bean oil in myocardial infarction. Lancet 1968; ii: 693–700.

W2. Burr ML, et al. Effects of changes in fat, fish and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989; ii: 757–61.

W3. Buchwald H, et al. Effect of partial ileal bypass survey on mortality and morbidity from coronary heart disease in patients with hypercholesterolemia. N Engl J Med 1990; 323: 946–55.

W4. Singh RB, Rastogi SS, Verma R, Laxmi B, Singh R et al. Randomised controlled trial of cardioprotective diet in patients with recent acute myocardial infarction: results of one year follow up. BMJ 2002; 304: 1015-1019.

W5. de Lorgeril M, Renaud S, Mamelle N, Salen P, Martin JL, et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994;343:1454-1459.

W6. de Lorgeril M, Salen P, Martin J-L, Monjaud I, Delaye J, Mamelle N. Mediterranean Diet, Traditional Risk Factors and the Rate of Cardiovascular Complications After Myocardial Infarction. Final Report of the Lyon Diet Heart Study. Circulation 1999; 99: 779.

W7. Ornish D, Brown SE, Scherwitz LW. Can lifestyle changes reverse coronary heart disease? Lancet 1990; 336: 129–33.

W8. Schuler G, et al. Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease. Circulation 1992; 86: 1–11.

W9. Watts, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992; 339: 563–9.

W10. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 334: 1383–9.

W11. Sacks FM, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001–9.

W12. The long-term Intervention with Pravastin in Ischaemic Disease (LIPID) study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–57.

W13. Pitt B, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999; 341: 70–6.

W14. Tonkin AM, et al. for the LIPID Study Group. Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID Study. Lancet 2000; 355: 1871-5.

W15. Liem A, van Boven AdJ, Withagen AP, Robles de Medina RM, et al. Fluvastatin in Acute Myocardial Infarction: Effects on Early and Late Ischemia and Events: the FLORIDA Trial. Circulation 2000; 102(21): 2672-d.

W16. Schwartz GG, et al. Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes. The MIRACL Study: a randomized controlled trial. JAMA 2001; 285: 1711–18.

W17. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Heart Protection Study Collaborative Group. Lancet 2002; 360: 7-22

W18. Serruys PWJ, de Feyter P, Macaya C, Kokott N, Puel J, et al. Fluvastatin for Prevention of Cardiac Events Following Successful First Percutaneous Coronary Intervention: A Randomized Controlled Trial JAMA June 2002; 287(2); 3215.

W19. Brown G, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990; 323: 1289–98.

W20. Kane JP, et al. Regression of coronary atherosclerosis during treatment of familial hypercholesterolaemia with combined drug regimens. JAMA 1990; 264: 3007–12.

W21. Blankenhorn DH, et al. and the MARS Research Group: Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993; 119: 969–76.

W22. Waters D, et al. and the CCAIT Study Group: Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994; 89: 959–68.

W23. Haskell WL, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease. The Stanford Coronary Risk Intervention Project (SCRIP). Circulation 1994; 89: 975–90.

W24. MAAS Investigators: Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994; 344: 633–8.

W25. Thompson GR, et al. Familial Hypercholesterolaemia Regression Study: A randomised trial of LDL apheresis. Lancet 1995; 345: 811–16.

W26. Pitt B, et al. for the PLAC-1 Investigators: Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-1). Reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol 1995; 26: 1133–9.

W27. Jukema JW, et al. for the REGRESS Study Group. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men

with normal to moderately elevated cholesterol levels: The Regression Group Evaluation Statin Study (REGRESS). Circulation 1995; 91: 2528–40.

W28. Kroon AA, et al. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996; 93: 1826–35.

W29. Herd JA, Ballantyne CM, Farmer JA, Ferguson JJ III, Jones PH, West MS, Gould KL, Gotto AM Jr, for the LCAS Investigators. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997; 80: 278–86.

W30. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 1997; 336: 153–62.

W31. Brown BG, Zhao X-Q, Chait A, Fisher LD, Cheung MC, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345(22): 1583.

W32. Sacks FM, et al. for the Harvard Atherosclerosis Reversibility Project (HARP) group: Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients. Lancet 1994; 344: 1182–6.

W33. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231; 360–81.

W34. Carlson LS, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988; 223: 405–18.

W35. Bloomfield Rubins H, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341: 410–18.

W36. The BIP Study Group. The Befazafibrate Infarcation Prevention (BIP) Study: Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 2000; 102: 21-7.

W37. Nikkila EQ, Viikinkoski P, Valle M. Effect of lipid lowering treatment on progression of coronary atherosclerosis. A 7-year prospective angiographic study. Circulation 1983; 69 (suppl. III): 111–88.

W38. Levy RI, et al. The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease: results of the NHLBI type II coronary intervention study. Circulation 1984; 69: 325–37.

W39. Blankenhorn DH, et al. Beneficial effects of combined colestipol–niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987; 257: 3233–40.

W40. Cashin-Hemphill L, et al. Beneficial effects of Colestipol–Niacin on Coronary Atherosclerosis – a 4-year follow-up. JAMA 1990; 264: 3013–17.

W41. Ericsson C-G, et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarct patients. Lancet 1996; 347: 849–53.

W42. Frick MH, Syvänne M, Nieminen MS, et al. Prevention of teh angiographic progression of coronary and vein-graft atherosclerosis by gemifibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Circulation 1997; 96: 2137–2148.

W43. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357: 905–10

W44. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results: I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351–64.

W45. Shepherd J, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995; 333: 1301–7.

W46. Downs JR, Clearfield M, Weis DO et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615–22.

W47. Oliver MF, et al. A co-operativetrial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978: 40; 1069-118

W48. Frick MH, et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987; 317: 1237–45.

W49. Elkeles RS, et al. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: the St Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 1998; 21(4): 641–8.